Treatment.com AI Inc. Announces Listed Issuer Financing Exemption (Life) Bought Deal Private Placement
Not for distribution to United States newswire services or for release publication, distribution, or dissemination directly, or indirectly, in whole or in part, in or into the United States Vancouver, British Columbia, February 27, 2025 – Treatment.com AI Inc. (the “Company” or “Treatment”) (CSE: TRUE; OTC: TREIF; FFA: 939) is pleased to announce that it has entered into an agreement with Ventum Financial Corp., as underwriter (the “Underwriter”) and sole bookrunner in connection with a brokered private placement of 6,000,000 units (the “Units”) of the Company at a price of C$0.50 per Unit (the “Offering Price”) for gross proceeds to the Company of C$3,000,000 (the “Offering”). Each Unit will consist of one common share in the capital of the Company (a “Common Share”) and one-half of one Common Share purchase warrant of the Company (each whole warrant being, a “Warrant”). Each Warrant will entitle the holder thereof to purchase one Common Share of the Company (a “Warrant Share”) for a period of 24 months following the Closing Date (as hereinafter defined) at an exercise price of C$0.75 per Warrant Share. The Offering is being completed pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 – Prospectus Exemptions to purchasers resident in each of the provinces of Canada, except Quebec. The Units issued pursuant to the Offering will not be subject to a hold period in accordance with applicable Canadian securities laws. There is an offering document related to the Offering that can be accessed under the Company’s profile at www.sedarplus.ca and on the Company’s website at www.treatment.com. Prospective investors should read this offering document before making an investment decision. Upon closing of the Offering, the Company will (i) pay to the Underwriter a cash fee equal to 8.0% of the aggregate gross proceeds of the Offering and (ii) issue to the Underwriter warrants of the Company exercisable at any time prior to the date that is 24 months from the Closing Date to acquire that number of Units equal to 8.0% of the number of Units issued under the Offering, at an exercise price equal to the Offering Price, subject to adjustment in certain events. The Company intends to use the proceeds raised from the Offering for research and development, sales and general and administrative expenses and working capital. The Offering may close in tranches. The Offering is expected to close on or before March 12, 2025 (the “Closing Date”). The Offering is subject to certain conditions including, but not limited to, receipt of all necessary approvals including the approval of the Canadian Securities Exchange. The securities issued pursuant to the Offering have not, nor will they be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons in the absence of U.S. registration or an applicable exemption from the U.S. registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or in any other jurisdiction in which such offer, solicitation or sale would be unlawful. About Treatment.com AI Inc. Treatment.com AI is a company utilizing AI and best clinical practices to positively improve the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally, Treatment has built a comprehensive, personalized healthcare AI engine, the Global Library of Medicine (GLM). With more than ~10,000 expert medical reviews, the GLM delivers tested clinical information and support to all healthcare professionals, as well as providing recommended tests (physical and lab), x-rays, and billing codes. The GLM helps healthcare professionals (doctor, nurse or pharmacist) reduce their administrative burden; create more time for needed face to face patient appointments and enables greater consistency in quality of patient support. Treatment’s GLM platform, through supporting healthcare professionals, allows for the inclusion of disenfranchised communities. To learn more about Treatment’s products and services: www.treatment.com or email: info@treatment.com FOR ADDITIONAL INFORMATION, CONTACT: Dr. Essam Hamza, CEO ehamza@treatment.com For media inquiries, contact: media@treatment.com Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955 Cautionary Statement This news release contains forward-looking statements relating to the closing of the Offering and to future operations of Treatment and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the closing of the Offering, the use of proceeds of the Offering, and future plans and objectives of Treatment, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Treatment’s expectations include, amongst other things, failure to complete the Offering, the need to satisfy regulatory and legal requirements with respect to the Offering and other risks detailed from time to time in the filings made by Treatment with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Treatment. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and Treatment
Rocket Doctor Approved as In-Network Provider for New York Medicaid, Expands Partnership with EngageWell to Enhance Care
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) Announces Rocket Doctor’s Approval as an In-Network Provider for New York Medicaid Strengthening Access to Virtual Healthcare Across the State and Collaboration with EngageWell. Approved as an in-network provider for New York Medicaid, covering 6.9 million individuals (35% of the state’s population) Expands Rocket Doctor’s virtual healthcare services to Medicaid beneficiaries across New York Supports patients with urgent, primary, and specialty care via an advanced telehealth platform Service is designed to reduce ER visits, decrease wait times, and improve access to timely specialist referrals Advances Rocket Doctor’s mission to eliminate barriers to high-quality healthcare Partnership with EngageWell to enhance virtual care and support for aging New Yorkers funded by a US$1m grant NEW YORK, NY – February 25, 2025 – Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) is pleased to announce that Rocket Doctor and its virtual healthcare marketplace has been approved as an in-network provider for New York Medicaid. This milestone now provides the state’s 6.9 million Medicaid beneficiaries with direct access to Rocket Doctor’s high-quality virtual healthcare services. This approval significantly expands access to affordable medical care for approximately 35% of New York’s population, ensuring patients can receive timely treatment without unnecessary emergency room visits or long wait times. Starting January 22, 2025, Rocket Doctor’s board-certified physicians will offer primary, urgent, and specialty care to Medicaid recipients through its state-of-the-art telehealth platform, with accreditation valid until 2030. The partnership is a critical step in addressing healthcare disparities by connecting underserved communities with comprehensive, on-demand medical care from the comfort of their homes. “I believe this approval marks a turning point for Medicaid patients in New York,” said Dr. William Cherniak, CEO and Founder of Rocket Doctor. “By bringing our virtual and hybrid-care models to one of the largest Medicaid populations in the country, we are breaking down barriers and ensuring that patients, regardless of their location or financial status, can access the healthcare they need, when they need it.” Expanding support for Aging New Yorkers with EngageWell In addition to Rocket Doctor’s Medicaid expansion, the team is also proud to collaborate with EngageWell https://engagewellipa.com/, a network of health and human service organizations dedicated to serving low-income and underserved populations in New York City. Established in 2016 to support its providers in navigating New York’s shift to value-based care, EngageWell enhances care management for people with chronic health conditions and behavioral health disorders by strengthening virtual care infrastructure, expanding the role of Community Health Workers, and integrating innovative technology to improve access and outcomes. Through its flagship initiative, Care Your Way, EngageWell leverages telehealth, remote patient monitoring, and social determinants of health to address health disparities and connect individuals with the care they need. “EngageWell is committed to expanding access to care for Medicaid members and those who face systemic barriers to healthcare,” said Christopher Joseph, Executive Director of EngageWell IPA. “Through our partnership with Rocket Doctor and support from our provider network, we’re using telehealth and remote patient monitoring to advance health equity and connect people to the care they need. While grant funding is currently supporting Care Your Way and our efforts to demonstrate health and social impact, securing Medicaid approval is key to sustaining and scaling these efforts.” With services now live, clients served by any EngageWell provider can book virtual consultations with Rocket Doctor’s network of experienced physicians across more than 20 specialties. This advancement is expected to streamline access to outpatient care and drive significant improvements in healthcare outcomes, while reducing costs for both patients and the healthcare system. Rocket Doctor’s expansion into New York and partnership with EngageWell aligns with its broader mission to leverage innovative digital solutions to deliver equitable healthcare access across North America. The company plans to further partner with Medicaid and other healthcare providers to ensure that vulnerable populations receive the care they need. About Treatment.com AI Inc. Treatment.com AI is a company utilizing AI (artificial intelligence) and best clinical practices to positively improve the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally, Treatment.com AI has built a comprehensive, personalized healthcare AI engine — the Global Library of Medicine (GLM). With more than 10,000 expert medical reviews, the GLM delivers tested clinical information and support to all healthcare professionals as well as providing recommended tests (physical and lab), imaging and billing codes. The GLM helps healthcare professionals (doctors, nurses or pharmacists) reduce their administrative burden; creates more time for needed face-to-face patient appointments; and enables greater consistency in quality of patient support. Treatment.com AI’s GLM platform, through supporting healthcare professionals, allows for the inclusion of disenfranchised communities. To learn more about Treatment’s products and services: www.treatment.com or email: info@treatment.com About Rocket Doctor Inc. Rocket Doctor is a technology-driven digital health platform and marketplace that is breaking down obstacles that limit access to quality, comprehensive and cost-effective healthcare. Our proprietary software equips doctors with the tools to run successful practices in virtual and hybridized in-person/virtual models of care, enabling them to provide tailored care to patients in remote communities, particularly those in rural and Northern communities across Canada and on Medicaid in the United States. Leveraging large language models, AI/ML and wireless medical devices, Rocket Doctor is bridging the healthcare divide, connecting patients to equitable and accessible virtual healthcare services regardless of age, location, or financial status. This includes patients with potentially stigmatizing conditions such as substance use, mental health and otherwise. About EngageWell EngageWell IPA is a leading healthcare organization created in 2016 by New York City not-for-profit organizations working together to offer coordinated, integrated treatment options that include addressing social determinants of health — housing, nutrition, economic security. Through innovative clinical care models and strategic partnerships, EngageWell strives to create a more equitable healthcare system that addresses health disparities and breaks the links between poverty, structural racism, and poor health. www.engagewellipa.com To learn more about Rocket Doctor’s platform and services, visit www.rocketdoctor.io (U.S.) www.rocketdoctor.ca (Canada)
Treatment.com AI and Rocket Doctor CEO’s meet for a fireside chat to discuss the recently announced acquisition and the future of AI in healthcare
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, February 20, 2025 – Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) is pleased to advise that further to its announcement that it has entered into a Definitive Share Purchase Agreement dated February 12, 2025 (the “Definitive Agreement”) to acquire Rocket Doctor Inc. (“Rocket Doctor”), details of which are in Treatment’s Press Release dated 12th February 2025 https://www.treatment.com/press/, the CEO’s of Treatment.com AI and Rocket Doctor Inc have combined for a fireside chat to discuss in more detail the acquisition and its opportunities. They also cover the most recent Press Release dated February 19, 2025 https://www.treatment.com/rocket-doctor-signs-agreement-with-california-managed-care-plan/ Dr. Essam Hamza, CEO of Treatment.com AI and Dr. Bill Cherniak, CEO and Founder of Rocket Doctor meet with Penny Queen. They discuss their views on how Treatment and Rocket Doctor technologies can play a role in positively improving the healthcare sector and impact current inefficiencies and challenges. https://www.treatment.com/wp-content/uploads/2025/02/Treatment_Fireside_Chat_Rocket_Doctor_Safe.mp4 About Treatment.com AI Inc. Treatment.com AI is a company utilizing AI (artificial intelligence) and best clinical practices to positively improve the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally, Treatment.com AI has built a comprehensive, personalized healthcare AI engine — the Global Library of Medicine (GLM). With more than 10,000 expert medical reviews, the GLM delivers tested clinical information and support to all healthcare professionals as well as providing recommended tests (physical and lab), imaging and billing codes. The GLM helps healthcare professionals (doctors, nurses or pharmacists) reduce their administrative burden; creates more time for needed face-to-face patient appointments; and enables greater consistency in quality of patient support. Treatment.com AI’s GLM platform, through supporting healthcare professionals, allows for the inclusion of disenfranchised communities. To learn more about Treatment’s products and services: www.treatment.com or email: info@treatment.com About Rocket Doctor Inc. Rocket Doctor is a technology-driven digital health platform and marketplace that is breaking down obstacles that limit access to quality, comprehensive and cost-effective healthcare. Our proprietary software equips doctors with the tools to run successful practices in virtual and hybridized in-person/virtual models of care, enabling them to provide tailored care to patients in remote communities, particularly those in rural and Northern communities across Canada and on Medicaid in the United States. Leveraging large language models, AI/ML and wireless medical devices, Rocket Doctor is bridging the healthcare divide, connecting patients to equitable and accessible virtual healthcare services regardless of age, location, or financial status. This includes patients with potentially stigmatizing conditions such as substance use, mental health and otherwise. To learn more about Rocket Doctor’s platform and services, visit www.rocketdoctor.io (U.S.) www.rocketdoctor.ca (Canada) or email media@rocketdoctor.io. FOR ADDITIONAL INFORMATION, CONTACT: Dr. Essam Hamza, CEO ehamza@treatment.com For media inquiries, contact: media@treatment.com Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955 Cautionary Statements This news release contains forward-looking statements that are based on Treatment.com AI’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. These forward-looking statements or information may relate to the consummation of Rocket Doctor’s California Medicaid transaction and the expected benefits to Rocket Doctor of such transaction and other factors or information. Although Treatment.com believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Treatment.com undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Future Oriented Financial Information This news release also contains future-oriented financial information and financial outlook (collectively, “FOFI”) about Rocket Doctor’s forecasted revenues and gross margins from the partnership with a California managed care plan which is subject to the same assumptions, risk factors, limitations, and qualifications as set forth in the above paragraphs. FOFI contained in this news release was made by management as of the date of this news release and was provided for the purpose of providing readers with an understanding of the importance of such transactions to Rocket Doctor’s business, and are not an estimate of profitability or any other measure of financial performance. Readers are cautioned that the FOFI contained in this news release should not be used for purposes other than for which it is disclosed herein. The Company disclaims any intention or obligation to update or revise any FOFI contained in this News Release, whether as a result of new information, future events or otherwise, unless required pursuant to applicable law. FOFI contained in this news release should not be used for purposes other than for which it is disclosed herein. The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
Rocket Doctor Signs Agreement with California Managed Care Plan
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES Rocket Doctor partners with new Managed Care Plan serving ~450,000 California Medicaid members Future anticipated additional ARR of ~US$1.2 million Mission to break down barriers to healthcare access Reducing unnecessary ER visits, reducing wait times, timely specialist referrals VANCOUVER, British Columbia, February 19, 2025 – Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) is pleased to advise that further to its announcement that it has entered into a Definitive Share Purchase Agreement dated February 12, 2025 (the “Definitive Agreement”) to acquire Rocket Doctor Inc. (“Rocket Doctor”), details of which are in Treatment’s Press Release dated 12th February 2025 https://www.treatment.com/press/, Rocket Doctor has partnered with a California managed care plan (the “Plan”) serving approximately 450,000 Medicaid members, to provide tele-urgent care, specialty services, and primary care. Through this collaboration, Rocket Doctor’s innovative virtual care platform will support the plan’s extensive provider network of 14,000 clinicians and multiple hospitals, ensuring that patients can access high-quality medical care from the comfort of their homes. Under this fee-for-service agreement, Rocket Doctor’s physicians are now becoming fully credentialed, allowing them to accept patients from the plan and bill directly for reimbursement at negotiated rates. Services have already launched, with the first patients starting to receive care. As the partnership matures, and assuming only 10% utilization per year, Rocket Doctor expects upwards of 45,000 visits per year generating approximately US$1.2M per year of added annual recurring revenue (ARR). The associated estimated total billable value of services is US$4.41m (based on US$98 per visit). The anticipated gross margin in Year 1 is US$18/visit. The term of the Agreement is on a recurring 12 months basis commencing January 1st 2025, with a 120 day mutual termination clause. “This partnership represents a significant step forward in our mission to break down barriers to healthcare access for patients at greatest need across California,” said Dr. Bill Cherniak, CEO and Founder of Rocket Doctor. “By bringing high-quality care to Medicaid beneficiaries through managed care plan partnerships in California, we’re ensuring that patients can connect with physicians when and where they need them most, embedded deeply within the framework of the healthcare system.” The Plan sees the collaboration as a critical expansion of care options for its members. Rocket Doctor’s virtual care model reduces unnecessary emergency department (ED) visits, reduces wait times, and ensures timely specialist referrals. With services now live, eligible plan members can schedule virtual visits with board certified physicians across a range of medical specialties. Dr. Essam Hamza, CEO of Treatment.com AI, adds: “We would like to congratulate Bill and his team for all the hard work they have put into getting this significant deal across the finish line. I know that this was years in the making and it’s great to see that they can now start recognizing the revenue from this expansion into California. We will be watching closely as they continue to deliver on further expansion plans within the state as well as other states and provinces.” Rocket Doctor is a technology-driven digital health platform and marketplace that is breaking down obstacles limiting access to high quality, comprehensive and cost-effective healthcare. Its proprietary software equips doctors with ‘plug and play’ tools to run successful independent practices in virtual and hybridized in-person/virtual models of care, enabling them to provide tailored care to patients in remote communities, particularly those in rural and Northern communities across Canada and on Medicaid in the United States. About Treatment.com AI Inc. Treatment.com AI is a company utilizing AI (artificial intelligence) and best clinical practices to positively improve the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally, Treatment.com AI has built a comprehensive, personalized healthcare AI engine — the Global Library of Medicine (GLM). With more than 10,000 expert medical reviews, the GLM delivers tested clinical information and support to all healthcare professionals as well as providing recommended tests (physical and lab), imaging and billing codes. The GLM helps healthcare professionals (doctors, nurses or pharmacists) reduce their administrative burden; creates more time for needed face-to-face patient appointments; and enables greater consistency in quality of patient support. Treatment.com AI’s GLM platform, through supporting healthcare professionals, allows for the inclusion of disenfranchised communities. To learn more about Treatment’s products and services: www.treatment.com or email: info@treatment.com About Rocket Doctor Inc. Rocket Doctor is a technology-driven digital health platform and marketplace that is breaking down obstacles that limit access to quality, comprehensive and cost-effective healthcare. Our proprietary software equips doctors with the tools to run successful practices in virtual and hybridized in-person/virtual models of care, enabling them to provide tailored care to patients in remote communities, particularly those in rural and Northern communities across Canada and on Medicaid in the United States. Leveraging large language models, AI/ML and wireless medical devices, Rocket Doctor is bridging the healthcare divide, connecting patients to equitable and accessible virtual healthcare services regardless of age, location, or financial status. This includes patients with potentially stigmatizing conditions such as substance use, mental health and otherwise. To learn more about Rocket Doctor’s platform and services, visit www.rocketdoctor.io (U.S.) www.rocketdoctor.ca (Canada) or email media@rocketdoctor.io. FOR ADDITIONAL INFORMATION, CONTACT: Dr. Essam Hamza, CEO ehamza@treatment.com For media inquiries, contact: media@treatment.com Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955 Cautionary Statements This news release contains forward-looking statements that are based on Treatment.com AI’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. These forward-looking statements or information may relate to the consummation of Rocket Doctor’s California Medicaid transaction and the expected benefits to Rocket Doctor of such transaction and other factors or information. Although Treatment.com believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control
Treatment.com AI Enters into a Definitive Agreement to Acquire Rocket Doctor Inc. a Rapidly Growing Digital Health Company Empowering MDs to Provide Comprehensive Care to Patients Across the United States and Canada
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES Addition of ~[C$1.9] million unaudited ARR SaaS revenues Total Billable Value of Services increased to ~ C$7.1 million, up from C$4.3 million in 2023 Growing Network of over 300 doctors currently supporting up to 20 specialties (inc. GP Services, Women’s Health, Mental Health, Cardiology, Psychiatry, Internal Medicine, Pediatrics), 500,000 patient visits (over 650 per day) Enabling healthcare professionals to build next-generation virtual clinics, driving expansion of digital healthcare services across North America Addition of Rocket Doctor’s proprietary AI-powered digital health platform strengthens Treatment.com AI’s ability to drive innovation in healthcare Consideration of approximately C$11M in shares of Treatment.com with contingent consideration of up to approximately C$9.5M based on significant performance milestones VANCOUVER, British Columbia, February 12, 2025 – Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) is pleased to announce it has entered into a Definitive Share Purchase Agreement dated February 12, 2025 (the “Definitive Agreement”) with Rocket Doctor Inc. (“Rocket Doctor”) and the common shareholders of Rocket Doctor with respect to the proposed acquisition of 100% of the issued and outstanding securities in the capital of Rocket Doctor by Treatment (the “Proposed Transaction”). Rocket Doctor is a Canadian federally incorporated company which aims to transform the way healthcare is delivered, through empowering doctors to start their own virtual practices, thereby providing citizens with quick access to high-quality, comprehensive medical care, powered by advanced devices and proprietary technology. Dr. Essam Hamza, CEO of Treatment.com AI, comments: “We are thrilled to welcome the Rocket Doctor team into our ecosystem. Bill and Harry have built an innovative, proprietary, and rapidly growing platform that empowers physicians to build and seamlessly integrate digital and virtual care into their practices. As part of this acquisition, we plan to implement Treatment’s planned AI Nurse, leveraging our Global Library of Medicine (GLM) and our newly announced conversational voice application, to enhance patient triage and onboarding ahead of Rocket Doctor appointments. This will not only help create efficiency and aid the practitioners on the platform, but also provide a proof of concept for future commercial sales of Treatment’s software.” Rocket Doctor is a technology-driven digital health platform and marketplace that is breaking down obstacles limiting access to high quality, comprehensive and cost-effective healthcare. Its proprietary software equips doctors with ‘plug and play’ tools to run successful independent practices in virtual and hybridized in-person/virtual models of care, enabling them to provide tailored care to patients in remote communities, particularly those in rural and Northern communities across Canada and on Medicaid in the United States. Rocket Doctor is bridging the healthcare divide, integrating over a dozen unique tools into their own HIPAA-compliant electronic medical record (EMR) system, including artificial intelligence (AI) and large language models (LLM’s) to collect patient history in advance of the visit, automatically create medical notes, pull past medical records, provide language translation in over 200 languages, match the right patient to the right MD, and many other tools that will make the practice of medicine more efficient while enhancing the patient care experience. Since launching nearly 5 years ago, Rocket Doctor has powered over 300 MDs to provide care for over 500,000 patient visits across North America. Founded in Ontario Canada, Rocket Doctor has since expanded to Alberta, British Columbia and New Brunswick and in the United States, to California, Maryland and New York. Expansion in these territories has grown quickly with key partnerships with hospitals such as Georgian Bay General in Ontario and their virtual Emergency Department, Engagewell IPA and Federally Qualified Health Centers in NY and Central California Alliance for Health, a 450,000 member Medicaid managed care plan in California. Looking to the future, Rocket Doctor has a healthy pipeline of more provinces and states, as well as new B2B deals and growth within existing states and provinces, targeted for expansion in 2025. From 2023 to 2024, Rocket Doctor achieved 88% year-over-year growth in annual recurring revenue (ARR) of ~[C$1.9] million by the end of November 2024. In 2024, Rocket Doctor’ net loss was approximately [C$1.3] million compared to [C$2.4] million in 2023. During the same period, the total billable value of services increased from C$4.3 million in 2023 to C$7.1 million by the end of 2024. The total value of billable services include all billable services and fees billed by doctors utilizing the Rocket Doctor platform. All financial information with respect to Rocket Doctor is neither audited nor reviewed by an auditor and contains non-GAAP and non-IFRS measures such as MRR, ARR and total value of billable services. The financial information and non-GAAP, non-IFRS metrics are provided for context only and to provide some indication of the financial performance of Rocket Doctor. The financial information should not be relied upon for any other purpose than evaluating the transaction and not as indication of future performance of Rocket Doctor, Rocket Doctor has also been recognized by its peers and industry partners for its innovative approach and technology, with its goals of preventing low acuity patients from unnecessary ER visits and opening up access to quality, comprehensive and cost-effective healthcare for all. Amongst the awards are: 2024 Start-up Innovator of the Year Stanford Emergency Medicine (StEMI X) pitch contest 1st place Google for Startups AI First Accelerator Treatment and Rocket Doctor were both started and are led by clinicians. They share a common mission to ensure healthcare is trustworthy, relevant and available to everyone, and in so doing help reduce the administrative burden on healthcare professionals in our current healthcare systems. The proposed acquisition of Rocket Doctor opens up the potential for ready made partnerships with healthcare systems in the US and Canada for Treatment, as well as opportunities to increase presence within those partnerships. Equally, Rocket Doctor’s network of 300+ doctors creates the opportunity for a ready-made pilot environment for Treatment’s anticipated evolution of its GLM platform. Treatment and Rocket Doctor have both created proprietary technology solutions underpinned by AI/ML. As well as opportunities
Treatment.com AI Enters Into a Binding Letter of Intent to Acquire Alea Health Holdings Limited adding an AI Powered Voice Agent and Mental Health to its Platform
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES Strategic Expansion with Proposed Acquisition of Alea Health Holdings Limited, a UAE based AI company Proprietary Voice Agent using Conversational AI for onboarding and triaging patients Extended geographic reach – entry into the Middle East Healthcare market Advancing Mental Health Support using Alea’s proprietary and AI powered Mental Health Platform to Augment Primary and Specialist Care Enhanced Bench Strength: Expertise Driving Innovation VANCOUVER, British Columbia, January 28, 2025 – Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) is pleased to announce it has entered into a binding letter of intent dated January 28, 2025 (the “Letter of Intent”) with Alea Health Holdings Limited (“Alea Health”) for the proposed acquisition of Alea Health by Treatment (the “Proposed Transaction”). Alea Health is a UAE based technology company building innovative AI solutions for both primary and mental health care. Strategic Platform Expansion with Alea Health Alea Health has developed a proprietary online therapy platform that leverages AI-driven tools to address mental health challenges. Their platform incorporates conversational AI and voice technology to optimize patient intake and follow-up processes, reducing administrative burdens and enhancing patient engagement. The acquisition of Alea Health aligns with Treatment’s mission to deliver innovative AI solutions in healthcare and expand its capabilities in the rapidly growing mental health and AI-driven healthtech sectors. Harnessing Conversational AI for Healthcare Transformation Treatment has consistently been advocating for the utilization of conversational AI in all aspects of healthcare delivery over the next 5-10 years. Voice AI has the opportunity to impact many aspects of our current healthcare systems including: AI powered and automated Multi-Lingual Patient Intake, Triage and Assessment Streamlining of Healthcare Professionals Administrative Tasks Clinical Decision Support Remote Patient Monitoring and Post Hospital/Clinic Discharge follow ups Mental Health Support and Therapy The integration of Alea Health’s platform with Treatment’s proprietary Global Library of Medicine (GLM), a highly advanced and personalized AI healthcare engine, is aimed to enhance the company’s ability to deliver a unified and comprehensive solution tailored to meet the needs of healthcare systems worldwide. Extended Geographic Reach – UAE The GCC (Gulf Cooperation Council) announced at the end of 2024 (see: Revolutionizing Healthcare in the GCC: AI, Innovation & Data Impact) it expects to invest up to $135 billion to revolutionize healthcare through AI and data-driven innovation. With its presence in the UAE and an established pipeline of opportunities, Alea Health provides Treatment with a critical foothold in the region. This proposed acquisition represents Treatment’s first major investment in the Middle East, enabling the company to develop strong local relationships and tap into a market focused on modernizing healthcare delivery. Advancing Mental Health Support to Augment Primary Care The acquisition of Alea Health strengthens Treatment’s focus on integrating mental health services with primary care. Treatment’s Global Library of Medicine (GLM) currently supports over 1,000 diseases and 10,000 symptoms and risk factors, with plans to expand its mental health capabilities through 2025. Alea Health’s innovative approach combines AI and multi-modal analysis, including sentiment analysis and natural language processing of voice data, to enhance therapeutic matching and predict therapeutic alliance, a key driver of successful mental health outcomes. With a network of over 35 internationally licensed therapists, reflecting the diverse demographic segmentation of UAE residents, Alea Health’s online therapy platform offers patients the ability to select therapists, schedule and pay for sessions, and conduct therapy online. The platform also includes a 24/7 AI-powered mental health coach, providing continuous support between therapy sessions. Enhanced Bench Strength: Expertise Driving Innovation The entrepreneurial team behind Alea Health brings over 30 years of combined experience across AI, machine learning, SaaS, cloud services, and data science—critical components for successful healthtech solutions. With professional backgrounds spanning North America, Europe, and the UAE, the team has extensive expertise in mental health services, telemedicine, medical devices, hospital digital strategies, and patient intake software. This wealth of knowledge will further augment Treatment.com AI’s capabilities in delivering innovative solutions across the healthcare spectrum. The core team at Alea Health comprises: Richard Dallala – Chief Executive Officer (CEO) Richard brings over a decade of experience in healthcare technology and strategic consulting. As CEO of Alea Health, he leads the development of AI-powered mental health solutions with a focus on value-based care. Previously, Richard worked as a Management Consultant at McKinsey & Company, where he supported strategic engagements in various industries including healthcare. He also contributed to mental health initiatives as a New Services Manager at Dialogue Technologies, Mirah inc. and Cleveland Clinic Advisory. Richard holds a degree in Mechanical Engineering from McGill University, and his leadership continues to drive innovation in the healthcare sector. Saleh Paracha – Chief Technology Officer (CTO) A visionary technology leader, Saleh oversees the innovation and execution of Alea Health’s technology strategy. Under his leadership, the company launched an online therapy platform serving over 1,000 clients in its first month, integrating AI-driven chat, scheduling, and video conferencing capabilities. Saleh’s prior experience includes roles at Phreesia, where he maintained and augmented a $100M revenue-generating payment platform, and Dreamscape Labs, where he created SaaS augmented reality solutions. A graduate of the University of Waterloo with expertise in AI, SaaS, and cloud computing, Saleh excels at building scalable, secure platforms and fostering high-performing teams. Marco Bertetti – Chief Data Officer (CDO) & Chief Operating Officer (COO) Marco is a seasoned data scientist and operational strategist with a track record of building impactful data products. At Alea Health, he manages both data strategy and operational growth. His prior roles include Senior Data Scientist at Delivery Hero Talabat, where he optimized user incentives through machine learning, and Principal Data Scientist at Stint, where he established company-wide experimentation frameworks. Marco has also led advanced analytics teams at Skyscanner, creating machine learning-driven solutions. With academic foundations in data science and international economics from University College London and the University of Turin, Marco’s expertise enhances Alea Health’s innovation capacity while pursuing his PhD in natural language processing. Dr.
Treatment.com AI Inc. Announces Automatic Conversion of Special Warrants
Treatment.com special warrants to convert Dec. 27 Dr. Essam Hamza reports Treatment.com AI Inc. has filed a prospectus supplement dated Dec. 20, 2024, to its short form base shelf prospectus dated June 24, 2024, to qualify the distribution of securities underlying 2,138,766 special warrants issued by the company on Oct. 25, 2024. The prospectus supplement qualifies the distribution of 2,138,766 common shares and 1,069,383 common share purchase warrants comprising the units of the company issuable on the exercise or deemed exercise of the special warrants in the provinces of British Columbia, Alberta, Manitoba and Ontario. Each warrant entitles the holder thereof to acquire one common share at an exercise price of $1 until 5 p.m. Pacific Time for a period of 24 months. The special warrants will be deemed to be converted into common shares and warrants on Dec. 27, 2024. No action is required on the part of any holder of special warrants to convert their special warrants into underlying securities. The qualification rights of holders of special warrants are further described in the prospectus supplement and the shelf prospectus, which can be found under the company’s profile on SEDAR+. Access to the shelf prospectus, the prospectus supplement and any amendment to the documents is provided in accordance with securities legislation relating to procedures for providing access to a shelf prospectus supplement, a base shelf prospectus and any amendment. The shelf prospectus and the prospectus supplement are accessible on SEDAR+. An electronic or paper copy of the prospectus supplement, the corresponding shelf prospectus and any amendment to the documents may be obtained, without charge, from the company by e-mail at info@www.treatment.com and by providing the contact with an e-mail address or address, as applicable. About Treatment.com AI Inc. Treatment.com AI is a company utilizing AI (artificial intelligence) and best clinical practices to positively improve the health care sector and impact current inefficiencies and challenges. With the input of hundreds of health care professionals globally, Treatment.com AI has built a comprehensive, personalized health care AI engine — the Global Library of Medicine (GLM). With more than 10,000 expert medical reviews, the GLM delivers tested clinical information and support to all health care professionals as well as providing recommended tests (physical and lab), X-rays and billing codes. The GLM helps health care professionals (doctors, nurses or pharmacists) reduce their administrative burden; creates more time for needed face-to-face patient appointments; and enables greater consistency in quality of patient support. Treatment.com AI’s GLM platform, through supporting health care professionals, allows for the inclusion of disenfranchised communities. We seek Safe Harbor.
Treatment.com AI Announces Release of New Medical Education Suite (MES) and Update on the AI Assessment Symposium 1st November, 2024
Treatment.com AI announces expanded and updated MES new releases Lead commercial participant at Global/North American Symposium on AI Assessment in Medical Education Further enhancements and solutions set for H2 2024 VANCOUVER, British Columbia, November 4th, 2024 – Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) is pleased to announce the launch of its updated Medical Education Suite (MES) to coincide withTreatment’s participation in a landmark Symposium on AI Assessment in Medical Education being hosted by the University of Minnesota Medical School on 1st November 2024. Medical Education Suite (MES) Release and Update It is estimated that over 80 countries globally have now adopted the OSCE (Objective Structured Clinical Examination) for assessing the practical clinical skills of medical students. It is estimated that between 200,000 and 300,000 medical students globally take the OSCE exam each year, as derived from indicative numbers of students from key professional bodies including: https://www.aamc.org/; https://www.uems.eu/; https://www.nmc.org.in/; Education – GMC (gmc-uk.org) As announced in a previous 2024 Press Releases,Treatment has been working diligently through 2024 to further evolve the Medical Education Suite (MES), powered by its proprietary Global Library of Medicine (GLM). The goal of furthering enhancements to the platform is the recognition that AI can be used even more effectively to reduce the administrative overhead and costs to schools in running OSCEs, as well providing greater support to medical students, thereby helping to optimize their clinical reasoning skills. Treatment’s service comprises of using its Global Library of Medicine platform (GLM) in (i) creating cases for the OSCE exams (ii) producing scripts for actors playing the role of patients (iii) scoring the exams with our proprietary automated marking platform and (iv) providing instant results to both faculty and students, as well as offering student enrichment plans. As part of this Release, Treatment is announcing the following additions to its portfolio: AI Patient – utilizing AI and a library of test Cases to further support students in their preparation and readiness for medical multiple-choice questions (MCQ’s) and OSCE exams. Objective Structured Clinical Examination (OSCE) Case Packages – the company is extending the number of test Cases provided from an initial 12 cases. These will be available in packs to schools and a planned library of up to 100 cases through Q4 2024. AI Prep Tool – the platform provides students with both a “guided” and “non-guided” support to learning. The “guided” approach provides students with learning support and reasoning, whereas the “non-guided” supports enables students to simulate exam conditions. Symposium on AI Assessment in Medical Education Together with the launch of its updated Medical Education Suite, Treatment is a lead participant in a Symposium on AI Assessment in Medical Education held on November 1, 2024 at the University of Minnesota Medical School, Office of Assessment and Evaluation. The creator of the Symposium, Dr. Claudio Violato described the event as a “landmark symposium”. (https://medtest.umn.edu/events) This academic Symposium includes more than fifty medical schools, thought leaders and national education examiners from across the US, as well as international representation. Presenters include Mayo Clinic, University of Alberta as well as Treatment’s Chief Medical Officer Kevin Peterson, MD, MPH, who will be a keynote speaker, as an acknowledged leader in medical education and its utilization of AI. Further enhancements and solutions for H2 2024 Treatment will continue to build out its Medical Education Suite through the rest of 2024 and early 2025. Further planned developments include: AI Doctor in a Pocket – delivers a mobile friendly AI powered clinical decision support tool for healthcare professionals and students when they are in clinics, residency or on a hospital ward. Audio/Video Analysis – using AI and the Global Library of Medicine to undertake Audio/Visual analysis which captures and transcribes the patient assessment. In addition, this will allow for behavioral analysis as part of exam scoring, as well as supporting the generation of a medical note. Dr. Essam Hamza, CEO of Treatment.com AI, comments: “We are excited to showcase our updated Medical Education Software Suite at this landmark Symposium. The opportunity to have a positive impact on the medical training of students and in turn introduce them to our range of proprietary AI tools is an important inflection point in the company’s commercialization timeline. We look forward to updating the market further in the near future. About Treatment.com AI Inc. Treatment.com AI is a company utilizing AI and best clinical practices to positively disrupt the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally, Treatment has built a comprehensive, personalized healthcare AI engine, the Global Library of Medicine (GLM). Providing highly qualified clinical information and support to all healthcare professionals, as well as providing recommended tests (physical and lab), x-rays, and billing codes. The GLM helps healthcare professionals (doctor, nurse or pharmacist) reduce their administrative burden; create more time for needed face to face patient appointments and has the propensity for greater consistency in quality of patient support. Treatment’s GLM platform also brings the possibility of health equity and inclusion for disenfranchised communities. To learn more about Treatment’s products and services: www.treatment.com or email: info@www.treatment.com FOR ADDITIONAL INFORMATION, CONTACT: Dr. Essam Hamza, CEO ehamza@www.treatment.com For media inquiries, contact: media@www.treatment.com Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955 Cautionary Statements This news release contains forward-looking statements that are based on Treatment.com AI’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although Treatment.com believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Treatment.com undertakes no obligation to update
Treatment.com Ai Inc. Closes Over-subscribed Non- Brokered Private Placement Of $1,954,074
Not for distribution to United States newswire services or for release publication, distribution, or dissemination directly, or indirectly, in whole or in part, in or into the United States. Vancouver, British Columbia, October 25, 2024 – Treatment.com AI Inc. (the “Company” or “Treatment”) (CSE: TRUE; OTC: TREIF; FFA: 939) is pleased to announce that, further to its news release dated October 4, 2024, it has closed a non-brokered private placement of 2,138,766 special warrants of the Company (each, a “Special Warrant”) at a price of $0.75 per Special Warrant, for aggregate gross proceeds of $1,604,074.50 and 466,666 units of the Company (each, a “Unit”) at a price of $0.75 per Unit, for aggregate gross proceeds of $349,999.50 (the “Offering”). Each Unit is comprised of one common share of the Company (each, a “Share”) and one-half of one Share purchase warrant (each whole warrant being, a “Warrant“) of the Company, with each Warrant exercisable into one Share at an exercise price of $1.00 for two (2) years from the date of issuance. Each Special Warrant will automatically convert, for no additional consideration, into one Unit on the date (the “Conversion Date”) that is the earlier of: (i) the third business day after the date of filing a prospectus supplement to a short form base shelf prospectus (the “Prospectus Supplement”) qualifying the distribution of the Shares and Warrants issuable upon the conversion of the Special Warrants, and (ii) 4 months and one day after the issue date of the Special Warrants. No Special Warrants may be exercised by the holder thereof prior to the Conversion Date Dr. Essam Hamza, CEO of the Company, stated: “We are very encouraged by the support from our investors with their overwhelming response to the financing and the subsequent over-subscription. This money will help expedite our aggressive growth plans over the next year.” In connection with the Offering, the Company has paid finder’s fees totalling $117,284 and issued an aggregate of 156,378 non-transferable broker warrants (the “Broker Warrants”) to arm’s-length parties. Each Broker Warrant entitles the holder to purchase one Share at an exercise price of $1.00 per Share for a period of two (2) years from the date of closing. The Company intends to use the proceeds raised from the Offering for working capital purposes. Prior to the filing of a Prospectus Supplement, the Special Warrants and the securities issuable upon conversion of the Special Warrants are subject to a statutory hold period of four months plus one day from the date of issuance in accordance with applicable securities legislation. The Units issued today and the Broker Warrants are subject to a statutory hold period of four months plus one day from the date of issuance in accordance with applicable securities legislation. The Special Warrants and Warrants will not be listed on any stock exchange or over-the-counter market. The securities issued pursuant to the Offering have not, nor will they be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons in the absence of U.S. registration or an applicable exemption from the U.S. registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or in any other jurisdiction in which such offer, solicitation or sale would be unlawful. About Treatment.com AI Inc. Treatment.com AI is a company utilizing AI and best clinical practices to positively improve the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally, Treatment has built a comprehensive, personalized healthcare AI engine, the Global Library of Medicine (GLM). With more than ~10,000 expert medical reviews, the GLM delivers tested clinical information and support to all healthcare professionals, as well as providing recommended tests (physical and lab), x-rays, and billing codes. The GLM helps healthcare professionals (doctor, nurse or pharmacist) reduce their administrative burden; create more time for needed face to face patient appointments and enables greater consistency in quality of patient support. Treatment’s GLM platform, through supporting healthcare professionals, allows for the inclusion of disenfranchised communities. To learn more about Treatment’s products and services: www.treatment.com or email: info@www.treatment.com FOR ADDITIONAL INFORMATION, CONTACT: Dr. Essam Hamza, CEO ehamza@www.treatment.com For media inquiries, contact: media@www.treatment.com Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955 Cautionary Statement This news release contains forward-looking statements relating to the future operations of Treatment and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the Offering, the use of proceeds of the Offering, the filing of a prospectus supplement and future plans and objectives of Treatment, are forward- looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Treatment’s expectations include other risks detailed from time to time in the filings made by Treatment with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Treatment. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking
Treatment.com AI Announces Non-Brokered Private Placement of up to $1,750,000 of Special Warrants
Not for distribution to United States newswire services or for release publication, distribution, or dissemination directly, or indirectly, in whole or in part, in or into the United States. Vancouver, British Columbia, October 4, 2024 – Treatment.com AI Inc. (the “Company” or “Treatment”) (CSE: TRUE; OTC: TREIF; FFA: 939) is pleased to announce that it is undertaking a non-brokered private placement of up to 2,333,333 special warrants of the Company (each, a “Special Warrant”) at a price of $0.75 per Special Warrant, for aggregate gross proceeds of up to $1,750,000 the (“Offering”). Each Special Warrant will automatically convert into one unit of the Company (each a “Unit”). Each Unit shall consist of one common share of the Company (a “Share”) and one-half of one common share purchase warrant (each full warrant, a “Warrant”). Each Warrant shall entitle the holder thereof to acquire one Share at a price of $1.00 per Share for a period of 24 months following the date of issuance of the Warrants. Each Special Warrant will automatically convert, for no additional consideration, into Units on the date (the “Conversion Date”) that is the earlier of: (i) the third business day after the date of filing a prospectus supplement to a short form base shelf prospectus (the “Prospectus Supplement”) qualifying the distribution of the Shares and Warrants issuable upon the conversion of the Special Warrants, and (ii) 4 months and one day after the issue date of the Special Warrants. No Special Warrants may be exercised by the holder thereof prior to the Conversion Date. The Company will use its commercially reasonable efforts to file the Prospectus Supplement to qualify the distribution of the Shares and Warrants issuable upon conversion of the Special Warrants within 60 days of the closing of the Offering (not including the date of closing). The Company may pay a finder’s fee of up to 8% of the gross proceeds of the Offering and may issue to certain eligible finders non-transferable broker warrants (the “Broker Warrants”) equal up to 8% of the number of Special Warrants sold under the Offering. Each Broker Warrant will entitle the holder to purchase one Share (a “Broker Share”) at an exercise price of $1.00 per Broker Share for a period of 24 months from the date of issuance of the Broker Warrants. The Company intends to use the proceeds raised from the Offering for working capital purposes. The Offering is expected to close on or before October 11, 2024. The Offering is subject to certain conditions including, but not limited to, receipt of all necessary approvals including the approval of the Canadian Securities Exchange. Prior to the filing of the Prospectus Supplement and the automatic conversion of the Special Warrants, all securities issued in connection with the Offering will be subject to a statutory hold period of four months plus one day from the date of issuance in accordance with applicable securities legislation. The Offering is not subject to a minimum aggregate amount of subscriptions. The securities being referred to in this news release have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the U.S. or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements. This news release does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. About Treatment.com AI Inc. Treatment.com AI is a company utilizing AI and best clinical practices to positively improve the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally, Treatment has built a comprehensive, personalized healthcare AI engine, the Global Library of Medicine (GLM). With more than ~10,000 expert medical reviews, the GLM delivers tested clinical information and support to all healthcare professionals, as well as providing recommended tests (physical and lab), x-rays, and billing codes. The GLM helps healthcare professionals (doctor, nurse or pharmacist) reduce their administrative burden; create more time for needed face to face patient appointments and enables greater consistency in quality of patient support. Treatment’s GLM platform, through supporting healthcare professionals, allows for the inclusion of disenfranchised communities. To learn more about Treatment’s products and services: www.treatment.com or email: info@www.treatment.com FOR ADDITIONAL INFORMATION, CONTACT: Dr. Essam Hamza, CEO ehamza@www.treatment.com For media inquiries, contact: media@www.treatment.com Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955 Cautionary Statements This news release contains forward-looking statements relating to the future operations of Treatment and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the Offering, the use of proceeds of the Offering, the filing of a Prospectus Supplement and future plans and objectives of Treatment, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Treatment’s expectations include other risks detailed from time to time in the filings made by Treatment with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Treatment. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking